We Appreciate Your Feedback!
Your input is invaluable to us in developing new modules and continuing to provide a positive user experience. Send your comments to Derek.Middleton@rlbuht.nhs.uk
Thank you in advance for your participation.
NEW VENTURE TO HELP SENSITISED RENAL RECIPIENTS
Contact Derek.Middleton@rlbuht.nhs.uk for further information.
We would also be very glad to receive new populations even if you have not previously contributed to the website.
Go to EUROSTAM website
We appreciate the previous help you have given to the AFND website (www.allelefrequencies.net). As you may know, the frequency data from your population is already on the website. However, we wish to move this on a further step and to use the data in another scheme which will help difficult to transplant patients, i.e. ďa hope for a future transplantĒ. You may have read a recent EFI Newsletter in which Frans Claas summarised a FP7 grant. The aim of the grant is to expand the very successful Eurotransplant scheme of Acceptable Mismatch Program to aid those highly sensitised patients (HSP) to receive a kidney. Basically, if a HSP patient is not successful at obtaining a transplant from a donor in their own country which other country might have a suitable donor.
The aim is to actually expand the scheme to other countries and for kidneys to be exchanged between countries for these HSP patients. Our role is to collect HLA data in normal patients in all the countries of Europe. You have already helped by providing the frequency data from your population or populations. However, for the scheme to output the Acceptable Mismatch program for all patients in Europe and to exchange kidneys for these specialised group of patients, we need to have the phenotypes of the individuals who make up the frequency data. Obviously, this will be provided anonymously. We donít need to know anything about the individuals, save that they are part of your normal population data. You donít even have to provide this for your existing population on allelefrequencies.net. If you have new data that will be very acceptable.
Data at either low or high resolution is acceptable and you can rest assured that the benefits of using your data will be communicated to you. It is also the intention (EFI willing) to keep everyone up to date via EFI Newsletter and EFI meetings. We hope and trust that you will see fit to taking part in this venture. The HLA community is renown throughout Europe for helping each other and our patients.
We have now migrated our website to a different server. We hope that the community will benefit from this change. While all searches have been tested to make sure they will work, please report to us any problem that you may find in the website.
The Allele Frequency Net Database (AFND) provides a central source, freely available to all, for the storage of allele frequencies from different polymorphic areas in the Human Genome. Users can contribute the results of their work into one common database and can perform database searches on information already available.
We have currently collected data in allele, haplotype and genotype format. The success of this website will depend on you to contribute your data.Please cite this website using our last publication: Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Gonzalez-Galarza FF, Christmas S, Middleton D and Jones AR Nucleic Acid Research 2011, 39, D913-D919. [Full Text]
You should also cite the original publication report of the data in your references.
The current number of frequencies stored in our database is: 94,211 (HLA), 5,303 (KIR), 3,618 (Cytokine) and 760 (MIC) from 4,505,425 individuals.
We have updated the website with the new IMGT/HLA nomenclature guidelines.
IMGT/HLA last Update: 3.14.0, 11 October, 2013. | IPD-KIR last Update: 2.4.0, 15 April, 2011.
AFND is part of EUROSTAM (an FP7-HEALTH collaborative project) to facilitate transplantation of highly sensitized patients.
|©2013 The Allele Frequency Net Database|
|Site Map | System Requirements|